RecruitingAdenocarcinoma (NOS)Anal CancerBladder Cancer

DESTINY-PANTUMOUR04

Eligible age

18–130 yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Sponsor: AstraZeneca

You may qualify if…

✓ 1. Adults aged ≥18 years
✓ 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);
✓ 3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;
✓ 4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;
✓ 5. Patients who are willing and able to provide a signed and dated informed consent.

You may not qualify if…

✕ 1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;
✕ 2. Prior T-DXd therapy;
✕ 3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.
✕ 4. Patient is participating in a clinical trial at time of enrolment